Affimed to Participate in Upcoming Investor Conferences
November 01, 2023 06:30 ET
|
Affimed N.V.
MANNHEIM, Germany, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed” or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their innate...
Affimed Announces Listing Transfer to Nasdaq Capital Markets
October 04, 2023 06:30 ET
|
Affimed N.V.
MANNHEIM, Germany, Oct. 04, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Announces Acceptance of an Abstract Comparing NK Cells Redirected by Innate Cell Engagers and CAR-NK Cells for Poster Presentation at the 38th Annual Meeting of the Society for Immunotherapy of Cancer
September 27, 2023 09:05 ET
|
Affimed N.V.
MANNHEIM, Germany, Sept. 27, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed to Present at the Cantor Global Healthcare Conference 2023
September 21, 2023 06:30 ET
|
Affimed N.V.
MANNHEIM, Germany, Sept. 21, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD) (“Affimed”, or the “Company”), a clinical-stage immuno-oncology company committed to giving patients back their...
Affimed Receives FDA Fast Track Designation for AFM13 in Combination with AlloNK® for the Treatment of Patients with Relapsed or Refractory Hodgkin Lymphoma
September 12, 2023 06:30 ET
|
Affimed N.V.
AFM13 in combination with AlloNK® (also known as AB-101) will be investigated in the LuminICE-203 open-label, multi-center, multi-cohort, phase 2 study evaluating the efficacy and safety of the...
Affimed to Present at the H.C. Wainwright Annual Global Investment Conference
September 07, 2023 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, Sept. 07, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Announces Publication in the Journal mAbs on Leveraging FcRn-pH-HPLC as a Method to Select Bispecific Antibodies with Optimal Developability
August 22, 2023 05:00 ET
|
Affimed N.V.
By coupling the chromatography method FcRn-HPLC to a pH monitor, an optimized FcRn-pH-HPLC methodology was developed allowing correlation of antibodies’ serum half-life with FcRn column dissociation...
Affimed Reports Second Quarter 2023 Financial Results and Highlights Operational Progress
August 10, 2023 06:30 ET
|
Affimed N.V.
AFM13 combination with AB-101 NK cells (LuminICE-203): On track to report initial efficacy and safety data in the first half 2024; Type C meeting request submitted to FDA to clarify requirements for...
Affimed to Report Second Quarter 2023 Financial Results & Corporate Update on August 10, 2023
August 03, 2023 06:30 ET
|
Affimed N.V.
HEIDELBERG, Germany, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Affimed N.V. (Nasdaq: AFMD), a clinical-stage immuno-oncology company committed to giving patients back their innate ability to fight cancer,...
Affimed Announces an ASCO Breakthrough Poster Presentation with Clinical Data of AFM24 in Combination with NKGen Biotech’s SNK01 NK Cells
July 31, 2023 17:05 ET
|
Affimed N.V.
Stable disease was observed in three out of seven heavily pretreated patientsNo dose-limiting toxicities or unexpected toxicities were observed HEIDELBERG, Germany, July 31, 2023 (GLOBE NEWSWIRE)...